(Alliance News) - European stocks were mixed in early dealings on Thursday, with markets awaiting a fresh set of catalysts after Nvidia beat on earnings overnight. Read More
(Alliance News) - The FTSE 100 reached fresh heights on Wednesday, with well-received results from HSBC, and gains in mining stocks, paving the way for another record-breaking day. Read More
(Alliance News) - Avacta Group PLC on Tuesday saw its shares rise, as it said new data demonstrates a favourable delivery profile and advantages of its preCision platform when compared to a marketed antibody drug conjugate. Read More
(Alliance News) - Stock prices in Europe moved lower in early dealings on Monday, with enthusiasm at the start of the week tempered by tariff uncertainty, as US President Donald Trump hit out at a Supreme Court ruling and announced new trade curbs. Read More
(Alliance News) - Stock prices in London were modestly lower at midday on Friday, with sentiment cautious ahead of US inflation data and the Munich Security Conference in focus. Read More
(Alliance News) - NatWest beats annual earnings expectations and boosts shareholder returns, while AstraZeneca reports positive late-stage trial data for Breztri in asthma, as UK retail footfall improves from a weak Christmas period but remains below last year's levels. Read More
(Alliance News) - Stock prices in London closed mixed on Wednesday, following news that the US labour market added almost double the amount of jobs expected last month. Read More
(Alliance News) - Stock prices in London opened lower on Tuesday, as a heavy slate of company results weighed on sentiment, with weakness in heavyweight stocks offsetting pockets of strength elsewhere in the market. Read More
(Alliance News) - AstraZeneca PLC on Tuesday declared a higher total dividend, as it posted increased revenue and profit for 2025 and hailed its "harmonised listing structure" following its recent debut on the New York Stock Exchange. Read More
(Alliance News) - BP suspends its share buyback programme as the oil major seeks to strengthen its balance sheet, while Barclays posts higher annual profit and earnings per share, and AstraZeneca lifts revenue and profit for 2025 while guiding for further growth in 2026. Read More
